Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note that the ANZCTR website will be unavailable from 1:00pm until 2:30pm (AEST) on Thursday 5th June for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000426482
Ethics application status
Approved
Date submitted
17/04/2025
Date registered
8/05/2025
Date last updated
8/05/2025
Date data sharing statement initially provided
8/05/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
Clinical validation and value proposition of Next Generation Malaria Rapid Diagnostic Test in Lao People's Democratic Republic
Query!
Scientific title
Clinical validation and value proposition of Next Generation Malaria Rapid Diagnostic Test (RDT) among individuals suspected of having malaria in Lao People's Democratic Republic (PDR): a diagnostic accuracy study with nested mixed methods
Query!
Secondary ID [1]
314207
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malaria
337103
0
Query!
Condition category
Condition code
Infection
333523
333523
0
0
Query!
Other infectious diseases
Query!
Public Health
333524
333524
0
0
Query!
Health service research
Query!
Public Health
333532
333532
0
0
Query!
Epidemiology
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intervention: a new "Next Generation" rapid diagnostic test (RDT) with a combined HRP2 and LDH line (SD Biosensor P. f/P. v Combo RDT).
Brief Name: NextGen RDT.
WHY: To assess diagnostic accuracy of NextGen RDTs in malaria case detection.
WHAT Materials:
- NextGen RDT usage instructions and information materials, in Lao language
- informed consent form for people requiring malaria testing
- malaria testing and treatment form (N1 form)
- filter paper for dried blood spots
- SD Biosensor P. f/P. v Combo RDT kit, including the test device, buffer, sterile lancet, and alcohol swab.
- zip lock bag and desiccant for shipment of dried blood spots
- unique identifier stickers
WHAT Procedures:
The Community Health Workers (CHWs) who are providing malaria services in the study area will be invited to use the NextGen RDTs in their malaria testing or screening activities, including active, passive and reactive case detections in the community setting. Community members who are identified for malaria testing in routine practice will be invited into the study to be tested by the NextGen RDT, in addition to the current standard (conventional) RDT, and to also have dried blood spots (DBS) collected for polymerase chain reaction (PCR) testing, the reference (gold standard) for detecting malaria parasites. CHWs will provide information on the study and seek informed consent prior to any testing. If the person agrees to participate, they will be enrolled in the study.
After receiving consent from the person to be tested, CHWs will perform malaria testing using the NextGen RDTs and current standard RDT; the RDT results will be read within 15 minutes and recorded at the point of care. the whole process of RDTs testing will take approximately 30 minutes. CHWs will also take two or three drops of whole blood on the filter paper to get the DBS. The blood for both RDTs and the DBS will be taken from the same finger prick, using a single lancet (supplied in the RDT kits). Participant information will be recorded on an ‘N1’ form, including the results of the RDTs and any treatments given. The standard case report form (F1 form) will also be filled in for positive cases as per routine practice. A photo of the RDTs will be taken for quality control purposes. The DBSs will be put in a zip lock bag for shipment to Laos Centre of Malariology, Parasitology and Entomology’s (CMPE) laboratory in Vientiane. The RDTs, DBS, N1 form, and zip lock bag will be deidentified by putting code stickers with unique identifiers. Individuals with a positive result by routine standard RDT will be treated for malaria as per the National Malaria Treatment Guidelines. If the NextGen RDT is positive when the standard RDT is negative (for either species), the CHW will refer the case to the microscopy centre for confirmation; if this is not feasible, the individual will be treated for the NextGen RDT positive result as per the National Malaria Treatment Guidelines.
The DBS will be stored and shipped at the end of each month to the CMPE’s laboratory in Vientiane where the PCR is available per standard operating procedures. The DBS will be tested with PCR for malaria parasites species, their density in blood and hrp2/3 deletions in P. falciparum confirmed infections suspected of hrp2/3 deletion (NextGen RDT positive and standard RDT negative for P.f) and as a result of false negative currently used RDT test results in samples with strong PCR signal (low Ct values).
WHO Provided:
The intervention is being provided by CHWs. CHWs in Lao PDR are trained to perform malaria diagnosis using RDTs and to provide malaria treatment as per the National Malaria Treatment Guidelines if RDT result is positive. Within this study, CHWs will get training of eight hours on the operation of NextGen RDTs, collecting dried blood spot (DBS), data and sample storage, and shipment at least two weeks prior to the start of the intervention. Usage instruction and information materials of NextGen RDT will be translated into Laos and the training will be delivered in local language by national trainers (Health Poverty Action (HPA) [Laos] staff).
HOW & WHERE: NextGen RDTs will be delivered via normal malaria testing and screening activities, within the CHW program. This will include:
• Passive case detection: occurring at the CHWs place of work (usually their home)
• Active case detection: occurring in the field, e.g. screening at check points.
• Reactive case detection: occurring after detecting an index malaria case in the area
WHEN AND HOW MUCH: The NextGen RDT will be used only once, for each suspected malaria episode. Participants can be enrolled more than once across different episodes.
TAILORING: None.
HOW WELL: If the CHW has access to a smart phone, they will be instructed to take a picture of the RDTs labelled with unique identifier stickers for quality assurance purposes (i.e. to check that a valid result has been produced, and that it has been interpreted correctly).
Query!
Intervention code [1]
330810
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
No control group (diagnostic accuracy study)
Gold standard test: Polymerase chain reaction (PCR) is used as the reference comparator for NextGen RDT and standard malaria RDT for the detection of Plasmodium spp. infection.
Both the intervention test (NextGen RDT) and the current standard malaria RDT will be evaluated for accuracy against PCR.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
341100
0
NextGen RDT sensitivity
Query!
Assessment method [1]
341100
0
Sensitivity with 95% confidence intervals is assessed by comparing test results from NextGen RDT against PCR amongst all participants. Results will be presented overall, and stratified by case finding strategy (passive, active, and reactive/focal).
Query!
Timepoint [1]
341100
0
At the time of malaria testing (diagnostic study).
Query!
Primary outcome [2]
341121
0
NextGen RDT specificity
Query!
Assessment method [2]
341121
0
Specificity with 95% confidence intervals is assessed by comparing test results from NextGen RDT against PCR amongst all participants. Results will be presented overall, and stratified by case finding strategy (passive, active, and reactive/focal).
Query!
Timepoint [2]
341121
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [1]
446229
0
NextGen RDT negative predictive value (NPV).
Query!
Assessment method [1]
446229
0
NPV with 95% confidence intervals is assessed by comparing test results from NextGen RDT against PCR amongst all participants. Results will be presented overall, and stratified by case finding strategy (passive, active, and reactive/focal).
Query!
Timepoint [1]
446229
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [2]
446230
0
Current RDT diagnostic accuracy.
Query!
Assessment method [2]
446230
0
Estimate the sensitivity, specificity, negative predictive value, and positive predictive value (with 95% confidence intervals), collectively as diagnostic accuracy, by comparing test results from current RDT against PCR amongst all participants. Results will be presented overall, and stratified by case finding strategy (passive, active, and reactive/focal).
Query!
Timepoint [2]
446230
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [3]
446354
0
Ability of the NextGen RDT to enhance identification of Plasmodium spp. infections.
Query!
Assessment method [3]
446354
0
The difference (with 95% CI) in the number of Plasmodium spp. infections (confirmed by PCR) detected by the NextGen RDT compared to the current RDT, per 1000 tests conducted, overall and within passive, active, and reactive/focal case-finding strategies.
Query!
Timepoint [3]
446354
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [4]
446355
0
Total implementation cost (US$) of switching to NextGen RDTs (start-up costs).
Query!
Assessment method [4]
446355
0
Calculation of one off and continuous (ongoing) costs to CMPE related to switching from the current standard RDT to NextGen RDTs for malaria testing in Laos. The cost data will be collected from study expenditure reports produced by Burnet, HPA and CMPE.
Query!
Timepoint [4]
446355
0
Over the duration of the intervention period.
Query!
Secondary outcome [5]
446356
0
Themes regarding the acceptability of the NextGen RDTs to the CHWs providing malaria diagnostic services in Lao PDR
Query!
Assessment method [5]
446356
0
Themes regarding the acceptability will be determined through focus group discussions and individual semi-structured in-depth interviews (conducted face-to-face by a member of the research team) with CHWs, by apply inductive and deductive coding to the qualitative data, adopting the position of critical realism within capacity, opportunity and motivation (COM-B) framework.
Query!
Timepoint [5]
446356
0
At the time of the focus group discussion and in-depth interviews, conducted within 3 months of the end of the intervention (last test).
Query!
Secondary outcome [6]
446357
0
Themes regarding feasibility to deploy the NextGen RDTs in different case-finding strategies in Lao PDR from the perspective of malaria program staff who oversee and design malaria control and elimination activities in Lao PDR.
Query!
Assessment method [6]
446357
0
Themes regarding the feasibility to deploy the NextGen RDTs will be determined through individual semi-structured in-depth interviews (conducted face-to-face by a member of the research team) with malaria program staff, by apply inductive and deductive coding to the qualitative data, adopting the position of critical realism within capacity, opportunity and motivation (COM-B) framework.
Query!
Timepoint [6]
446357
0
At the time of the interviews, administered within 3 months of the end of the intervention (last test).
Query!
Secondary outcome [7]
446358
0
Proportion of the CHWs who can comprehend the usage instruction (in Laotian) labelled on the package of NextGen RDTs and accurately interpret the results
Query!
Assessment method [7]
446358
0
NextGen RDT usability survey (designed for this study), conducted face-to-face with CHWs individually.
Query!
Timepoint [7]
446358
0
At the time of the survey, administered within 3 months of the end of the intervention (last test).
Query!
Secondary outcome [8]
446359
0
Percentage of P. falciparum cases detected by PCR with HRP2/3 deletion
Query!
Assessment method [8]
446359
0
PCR
Query!
Timepoint [8]
446359
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [9]
446360
0
Percentage breakdown by Plasmodium species, amongst cases diagnosed by PCR, NextGen RDT (excluding false positives) and current standard RDT (excluding false positives).
Query!
Assessment method [9]
446360
0
Descriptive statistics of the results from PCR, NextGen RDT, and current RDT
Query!
Timepoint [9]
446360
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [10]
447022
0
NextGen RDT positive predictive value (PPV).
Query!
Assessment method [10]
447022
0
PPV with 95% confidence intervals is assessed by comparing test results from NextGen RDT against PCR amongst all participants. Results will be presented overall, and stratified by case finding strategy (passive, active, and reactive/focal).
Query!
Timepoint [10]
447022
0
At the time of malaria testing (diagnostic study).
Query!
Secondary outcome [11]
447023
0
Incremental cost-effectiveness ratio (ICER) representing the difference in cost per additional case detected
Query!
Assessment method [11]
447023
0
Calculate the total per-unit cost (US$) of NextGen RDT and the current RDT and calculate the ICER for each additional case detected for CMPE. The cost data will be collected from study expenditure reports produced by Burnet, HPA and CMPE.
Query!
Timepoint [11]
447023
0
Over the duration of the intervention period.
Query!
Eligibility
Key inclusion criteria
Community members to be tested for malaria
o Individuals who live in the study villages or seek health services from community health workers (CHWs) (active, passive or reactive case detections). They may have signs and symptoms of malaria or be healthy individuals who carry parasite.
CHWs for focus group discussion and survey
o The workers must provide malaria services in the study area.
Malaria program stakeholder for in-depth interview
o The malaria program stakeholders must be stakeholders responsible for designing and overseeing the malaria control and elimination activities focusing diagnosis.
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
CHWs who are not assigned in the study area
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Sensitivity, specificity, positive and negative predictive values of NextGen RDT will be estimated with exact binomial 95% CI. Endpoints relating to the epidemiology of Plasmodium spp. and CHW comprehension and interpretation will be analysed descriptively (frequency and percentage). Further detail statistical analysis plan will be developed prior to data analysis.
The lower bound of the exact 95% confidence interval for an estimated sensitivity of 90% was calculated, assuming a total of 36,000 tests with current RDT will be conducted in the study area over 12 months across all testing strategies, a PCR test-positivity of 0.5%, a drop-out rate of 67% assuming only 33% (n=12,000) consent amongst the tested population (36,000) for testing with NextGen RDT and provide DBS for PCR testing, and a design effect of 2 to account for clustering. PCR test-positivity of 0.5% was based on RDT positivity rates in 2023-2024 within the study area (0.63% and declining), and RDT and PCR positivity rates in the Laos sites of the previous trial (0.46% and 1.84%, respectively). Based on these assumptions, 54 PCR-positive cases will be detected during the study amongst consenting participants, and the lower bound of the exact 95% confidence interval for an estimated sensitivity of 90% will be around 70% after accounting for clustering.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/06/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
31/05/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
30/08/2026
Query!
Actual
Query!
Sample size
Target
12000
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
26977
0
Lao People's Democratic Republic
Query!
State/province [1]
26977
0
Attapu, Champasak, Khammouan, Savannakhet, Salavan and Xekong,
Query!
Funding & Sponsors
Funding source category [1]
318723
0
Government body
Query!
Name [1]
318723
0
The Department of Foreign Affairs and Trade
Query!
Address [1]
318723
0
Query!
Country [1]
318723
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
PATH
Query!
Address
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
321159
0
Charities/Societies/Foundations
Query!
Name [1]
321159
0
Burnet Institute
Query!
Address [1]
321159
0
Query!
Country [1]
321159
0
Australia
Query!
Other collaborator category [1]
283472
0
Government body
Query!
Name [1]
283472
0
Centre of Malariology, Parasitology and Entomology
Query!
Address [1]
283472
0
Query!
Country [1]
283472
0
Lao People's Democratic Republic
Query!
Other collaborator category [2]
283473
0
Charities/Societies/Foundations
Query!
Name [2]
283473
0
Health Poverty Action Laos
Query!
Address [2]
283473
0
Query!
Country [2]
283473
0
Lao People's Democratic Republic
Query!
Other collaborator category [3]
283474
0
Charities/Societies/Foundations
Query!
Name [3]
283474
0
Community Health and Inclusion Association
Query!
Address [3]
283474
0
Query!
Country [3]
283474
0
Lao People's Democratic Republic
Query!
Other collaborator category [4]
283475
0
Charities/Societies/Foundations
Query!
Name [4]
283475
0
Population Education and Development Association
Query!
Address [4]
283475
0
Query!
Country [4]
283475
0
Lao People's Democratic Republic
Query!
Other collaborator category [5]
283476
0
University
Query!
Name [5]
283476
0
University of Melbourne
Query!
Address [5]
283476
0
Query!
Country [5]
283476
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
317335
0
Alfred Hospital Ethics Committee
Query!
Ethics committee address [1]
317335
0
https://www.alfredhealth.org.au/research/ethics-research-governance
Query!
Ethics committee country [1]
317335
0
Australia
Query!
Date submitted for ethics approval [1]
317335
0
17/02/2025
Query!
Approval date [1]
317335
0
28/03/2025
Query!
Ethics approval number [1]
317335
0
114649 (Local Reference: Project 27/25)
Query!
Ethics committee name [2]
317339
0
National Ethic Committee for Health Research
Query!
Ethics committee address [2]
317339
0
Lao Tropical and Public Health Institute Office, Ban Kaoyoth, Sisattanak district, Vientiane capital, Lao PDR; nechr2021@gmail.com; 021 214012
Query!
Ethics committee country [2]
317339
0
Lao People's Democratic Republic
Query!
Date submitted for ethics approval [2]
317339
0
02/04/2025
Query!
Approval date [2]
317339
0
Query!
Ethics approval number [2]
317339
0
Query!
Summary
Brief summary
Malaria is primarily diagnosed by community health workers using a conventional rapid diagnostic test which sensitivity and specificity are not optimal in the low transmission setting of Lao PDR. Next generation rapid diagnostic tests are available globally but have yet to be clinically validated in Lao PDR. This diagnostic accuracy study with mixed methods aims to evaluate the diagnostic accuracy, impact, cost-effectiveness, acceptability and feasibility of highly sensitive, next generation malaria rapid diagnostic tests to identify Plasmodium species infection to support malaria elimination in Lao PDR, in place of the current conventional RDT. This study will be implemented in 163 villages under 17 health facility catchment areas, across 12 districts in 6 provinces of Lao PDR: Attapeu, Champasak, Khammouan, Savannakhet, Salavan and Xekong. In this study, 12,000 individuals suspected of having malaria will be tested with conventional and next generation rapid tests as well as dried blood spot will be collected for polymerase chain reaction testing.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
140722
0
Dr Win Han Oo
Query!
Address
140722
0
Level 3, Building 379, 207 Bouverie Street, University of Melbourne, Victoria 3010
Query!
Country
140722
0
Australia
Query!
Phone
140722
0
+61390355446
Query!
Fax
140722
0
Query!
Email
140722
0
[email protected]
Query!
Contact person for public queries
Name
140723
0
Win Han Oo
Query!
Address
140723
0
Level 3, Building 379, 207 Bouverie Street, University of Melbourne, Victoria 3010
Query!
Country
140723
0
Australia
Query!
Phone
140723
0
+61390355446
Query!
Fax
140723
0
Query!
Email
140723
0
[email protected]
Query!
Contact person for scientific queries
Name
140724
0
Win Han Oo
Query!
Address
140724
0
Level 3, Building 379, 207 Bouverie Street, University of Melbourne, Victoria 3010
Query!
Country
140724
0
Australia
Query!
Phone
140724
0
+61390355446
Query!
Fax
140724
0
Query!
Email
140724
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
24642
Ethical approval
27-25 Ethics Approval 28-Mar-2025.pdf
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF